NCIP™: Extending the market opportunities for your existing drugs or restoring discontinued drug candidates back into clinical development
NCIP™ allows rapid analysis of drug action on human immune tissues and cells (normal resting or activated, or pathological) to predict potential therapeutic utility in a number of conditions (e.g. inflammation, autoimmune disease, allergy, prevention of graft rejection, lymphoma, leukaemia).
NCIP™ offers the opportunity to re-launch clinical progression of drugs that have stalled in development for their initial indication due to lack of (sufficient) efficacy. This provides the potential of revenue generation from already spent drug development costs.
To discuss our partnering opportunities please contact our Commercial Manager Dr Catherine Brady